Immunotherapy plus chemotherapy for stage III lung cancer
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stage III non-small cell lung cancer that cannot be surgically removed.
- You have not received any prior cancer treatment like chemotherapy, radiation, or immunotherapy.
- Your cancer does not have certain gene changes (EGFR, ALK, or ROS1) if it is a non-squamous type.
- You are in good overall health (able to do daily activities without help) and have adequate organ function.
- You are willing to use effective birth control during and for 8 weeks after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with stereotactic body radiation therapy (SBRT) for people with early-stage non-small cell lung cancer. The goal is to see if this treatment can help shrink or control the cancer before surgery.
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy given before surgery to remove stage III lung cancer. The goal is to shrink the tumor and improve survival chances by boosting your immune system to fight the cancer.
This trial tests if two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy can shrink stage III lung cancer that cannot be surgically removed, making it possible to operate. It is for people who have not had prior treatment for their lung cancer and are healthy enough for surgery.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.